Prognostic impact of the psoas muscle index, a parameter of sarcopenia, in patients with diffuse large B-cell lymphoma treated with rituximab-based chemoimmunotherapy

References

• Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107(1):265–276.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–242.
   PubMed Web of Science ®Google Scholar
• Xie Y, Pittaluga S, Jaffe ES. The histological classification of diffuse large B-cell lymphomas. Semin Hematol. 2015;52(2):57–66.
   PubMed Web of Science ®Google Scholar
• Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study [published correction appears in Blood. 2018 Feb 1;131(5):587–588]. Blood. 2017;130(16):1800–1808.
   PubMed Web of Science ®Google Scholar
• International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987–994.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857–1861.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837–842.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–511.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282.
   PubMed Web of Science ®Google Scholar
• Scott DW. Cell-of-origin in diffuse large B-cell lymphoma: are the assays ready for the clinic? Am Soc Clin Oncol Educ Book. 2015:e458–e466.
   PubMedGoogle Scholar
• Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013;121(20):4021–4031.
   PubMed Web of Science ®Google Scholar
• Go SI, Kim HG, Kang MH, et al. Prognostic model based on the geriatric nutritional risk index and sarcopenia in patients with diffuse large B-cell lymphoma. BMC Cancer. 2020;20(1):439. Published 2020 May 18.
   PubMed Web of Science ®Google Scholar
• Go SI, Park MJ, Song HN, et al. Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Cachexia Sarcopenia Muscle. 2016;7(5):567–576.
   PubMed Web of Science ®Google Scholar
• Chu MP, Lieffers J, Ghosh S, et al. Skeletal muscle radio-density is an independent predictor of response and outcomes in follicular lymphoma treated with chemoimmunotherapy. PLoS One. 2015;10(6):e0127589.
   PubMed Web of Science ®Google Scholar
• Chu MP, Lieffers J, Ghosh S, et al. Skeletal muscle density is an independent predictor of diffuse large B-cell lymphoma outcomes treated with rituximab-based chemoimmunotherapy. J Cachexia Sarcopenia Muscle. 2017;8(2):298–304.
   PubMed Web of Science ®Google Scholar
• Rier HN, Kharagjitsing H, van Rosmalen J, et al. Prognostic impact of low muscle mass and low muscle density in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2020;61(7):1618–1626.
   PubMed Web of Science ®Google Scholar
• Cruz-Jentoft AJ, Bahat G, Bauer J, Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31.
   PubMed Web of Science ®Google Scholar
• Hamaguchi Y, Kaido T, Okumura S, et al. Proposal for new diagnostic criteria for low skeletal muscle mass based on computed tomography imaging in Asian adults. Nutrition. 2016;32(11-12):1200–1205.
   PubMed Web of Science ®Google Scholar
• Kasahara R, Kawahara T, Ohtake S, et al. A low psoas muscle index before treatment can predict a poorer prognosis in advanced bladder cancer patients who receive gemcitabine and nedaplatin therapy. Biomed Res Int. 2017;2017:1–4.
   Web of Science ®Google Scholar
• Yuri Y, Nishikawa H, Enomoto H, et al. Implication of psoas muscle index on survival for hepatocellular carcinoma undergoing radiofrequency ablation therapy. J Cancer. 2017;8(9):1507–1516.
   PubMed Web of Science ®Google Scholar
• Tsutsumi S, Kawahara T, Teranishi JI, et al. A low psoas muscle volume predicts longer hospitalization and cancer recurrence in upper urinary tract urothelial carcinoma. Mol Clin Oncol. 2018;8(2):320–322.
   PubMed Web of Science ®Google Scholar
• Ishii N, Iwata Y, Nishikawa H, et al. Effect of pretreatment psoas muscle mass on survival for patients with unresectable pancreatic cancer undergoing systemic chemotherapy. Oncol Lett. 2017;14(5):6059–6065.
   PubMed Web of Science ®Google Scholar
• Ozawa Y, Nakano T, Taniyama Y, et al. Evaluation of the impact of psoas muscle index, a parameter of sarcopenia, in patients with esophageal squamous cell carcinoma receiving neoadjuvant therapy. Esophagus. 2019;16(4):345–351.
   PubMed Web of Science ®Google Scholar
• Ozeki N, Kawaguchi K, Fukui T, et al. Psoas muscle mass in patients undergoing lung cancer surgery: a prognostic difference between squamous cell carcinoma and adenocarcinoma. Int J Clin Oncol. 2020;25(5):876–884.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, International Harmonization Project on Lymphoma, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586.
   PubMed Web of Science ®Google Scholar
• Lanic H, Kraut-Tauzia J, Modzelewski R, et al. Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Leuk Lymphoma. 2014;55(4):817–823.
   PubMed Web of Science ®Google Scholar
• Nakamura N, Hara T, Shibata Y, et al. Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma. Ann Hematol. 2015;94(12):2043–2053.
   PubMed Web of Science ®Google Scholar
• Caram MV, Bellile EL, Englesbe MJ, et al. Sarcopenia is associated with autologous transplant-related outcomes in patients with lymphoma. Leuk Lymphoma. 2015;56(10):2855–2862.
   PubMed Web of Science ®Google Scholar
• Xiao DY, Luo S, O'Brian K, et al. Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy. Am J Hematol. 2016;91(10):1002–1007.
   PubMed Web of Science ®Google Scholar
• Go SI, Park MJ, Song HN, et al. A comparison of pectoralis versus lumbar skeletal muscle indices for defining sarcopenia in diffuse large B-cell lymphoma - two are better than one. Oncotarget. 2017;8(29):47007–47019.
   PubMedGoogle Scholar
• Fukushima H, Fujii Y, Koga F. Metabolic and molecular basis of sarcopenia: implications in the management of urothelial carcinoma. IJMS. 2019;20(3):760.
   Google Scholar
• Mijnarends DM, Meijers JM, Halfens RJ, et al. Validity and reliability of tools to measure muscle mass, strength, and physical performance in community-dwelling older people: a systematic review. J Am Med Dir Assoc. 2013;14(3):170–178.
   PubMed Web of Science ®Google Scholar
• Beaudart C, Reginster JY, Slomian J, et al. Estimation of sarcopenia prevalence using various assessment tools. Exp Gerontol. 2015;61:31–37.
   PubMed Web of Science ®Google Scholar